Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PH94B nasal spray for social anxiety disorder
NCT05011396Phase 3Terminated
- Sponsor
- Vistagen Therapeutics
- Start
- Aug 2021
- Primary completion
- Aug 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of fasedienol in Social Anxiety Disorder (SAD), sponsored by Vistagen Therapeutics. Started Aug 2021; status: terminated.
02
Drugs
fasedienol
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on NCT05011396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05011396.